Antibodies against tumor necrosis factor (TNF) and IL-6 receptor are the most effective available therapies against rheumatoid arthritis (RA). However, no cure for RA exists. In work published in Science Translational Medicine, scientists from Sanofi R&D (Sanofi SA) investigated whether dual inhibition of TNF and IL-6 could improve the therapeutic efficacy against RA.